390360-79-9

Basic information

• Product Name: Benzoic acid, 5-iodo-2-[(methylsulfonyl)amino]-, methyl ester
• CAS NO: 390360-79-9
• Molecular Formula: C9H10INO4S
• Molecular Weight: 355.153
• Mol File: 390360-79-9.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 5-iodo-2-[(methylsulfonyl)amino]-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 5-iodo-2-[(methylsulfonyl)amino]-, methyl ester(390360-79-9)
• EPA Substance Registry System: Benzoic acid, 5-iodo-2-[(methylsulfonyl)amino]-, methyl ester(390360-79-9)

Safety Data

• Hazardous Substances Data: 390360-79-9(Hazardous Substances Data)

Upstream product

• 3144-09-0 methanesulfonamide 
• 77317-55-6 methyl 2-amino-5-iodobenzoate 
• 124-63-0 methanesulfonyl chloride 

Downstream Products

• 865878-59-7 methyl 5-cyano-2-(methylsulfonamido)benzoate 
• 401907-32-2 5-[([4-(tert-butyl)benzyl]aminothiocarbonyl)amino]methyl-2-[(methylsulfonyl)amino]benzenecarboxylic acid 
• 401907-31-1 1-(4-t-butylbenzyl)-3-(3-methoxycarbonyl-4-methanesulfonyl-aminobenzyl) thiourea 
• 865878-65-5 5-[3-(4-tert-butyl-benzyl)-thioureidomethyl]-2-methanesulfonylamino-benzoyl chloride 

Relevant articles and documents

DHODH INHIBITORS AND THEIR USE AS ANTIVIRAL AGENTS

The present invention relates to a compound, or a dimer or a pharmaceutically acceptable salt or solvate of said compound or dimer, for use in a method for the treatment of a disease, disorder or condition caused by an RNA virus, said compound having the general structure shown in Formula (I).

Novel potent antagonists of transient receptor potential channel, vanilloid subfamily member 1: Structure-activity relationship of 1,3-diarylalkyl thioureas possessing new vanilloid equivalents

Recently, 1,3-diarylalkyl thioureas have merged as one of the promising nonvanilloid TRPV1 antagonists possessing excellent therapeutic potential in pain regulation. In this paper, the full structure-activity relationship for TRPV1 antagonism of a novel series of 1,3-diarylalky thioureas is reported. Exploration of the structure-activity relationship, by systemically modulating three essential pharmacophoric regions, led to six examples of 1,3-dibenzyl thioureas, which exhibit Ca2+ uptake inhibition in rat DRG neuron with IC50 between 10 and 100 nM.